Biochemistry, Epidermal Growth Factor Receptor


Article Author:
Morgan Murphrey


Article Editor:
Matthew Varacallo


Editors In Chief:
Rodrigo Kuljis
Oleg Chernyshev
Aninda Acharya


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Kyle Blair
Trevor Nezwek
Radia Jamil
Erin Hughes
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Navid Mahabadi
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Abbey Smiley
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Daniyal Ameen
Altif Muneeb
Beenish Sohail
Nazia Sadiq
Hajira Basit
Phillip Hynes
Komal Shaheen
Sandeep Sekhon


Updated:
4/21/2019 5:01:28 PM

Introduction

Epidermal growth factor receptor (EGFR), also known as ERBB, ERBB1, HER1, NISBD2, PIG61, and mENA, is a transmembrane glycoprotein with an intracellular tyrosine kinase that serves as a receptor for extracellular protein ligands. EGFR was the first member of the ErbB receptor family to be described. The ErbB receptors are a subfamily of four tyrosine kinase receptors including EGFR, HER-2/neu, HER-3, and HER-4. Ten different ligands can selectively bind to each receptor, and ligand binding leads to downstream pathways involved in cellular growth and proliferation as well as differentiation.[1][2][3]

EGFR overexpression is involved in multiple tumors and is associated with neurodegenerative diseases such as Alzheimer disease. The pathologies associated with EGFRs have led to novel treatment modalities, including monoclonal antibodies designed to inhibit EGFR signaling.

Fundamentals

EGFR was the first discovered epidermal growth factor receptor. Growth factor binding results in receptor dimerization, subsequent tyrosine kinase activity and autophosphorylation of specific tyrosine residues including Y992, Y1045, Y1068, Y1148, and Y1173. Eventual downstream activation of signal transduction cascades, including MAPK, Akt and JNK pathways, leads to DNA synthesis, cell proliferation, and differentiation.[4][5][6]

In considering EGFR, also known as ErbB-1, it is important to also consider the three related receptors of the ErbB family: ErbB-2, ErbB-3, and ErbB-4. ErbB-2 is also known as HER2 in humans and neu in rodents. In humans, the HER2 oncogene is associated with breast cancer and has become a target of therapy for associated breast cancers. ErbB-3 binds to heregulin and NRG-2. The function of ErbB-3 is yet unknown. ErbB-3 homodimers are non-functional; consequently, ErbB-3 is thought to be an allosteric activator of the other ErbB receptors. Finally, ErbB-4 binding results in mitogenesis and differentiation. Single-nucleotide polymorphisms of ErbB-4 have been implicated in amyotrophic lateral sclerosis type 19.

Function

EGFR binding by various ligands, including epidermal growth factor (EGF) and tumor growth factor-alpha (TGF-a), results in routine cellular processes such as proliferation, differentiation, and cellular development.[7][8][9]

EGFR is a 170 kDalton single polypeptide chain of 1186 amino acids expressed on the majority of human cells. This receptor is made up of an extracellular, intracellular and transmembrane region. The extracellular region facilitates ligand binding. Binding ligands include EGF, heparin-binding EGF-like growth factor (HB-EGF), TGF-a, amphiregulin, epiregulin, betacellulin, and epigen. These ligands share a conserved motif of six cysteines. The intracellular carboxy-terminal region is a tyrosine kinase. This tyrosine kinase autophosphorylates specific intracellular tyrosine residues, with Tyr-1173 serving as the major autophosphorylation site. The transmembrane region is a single hydrophobic anchor which traverses the cell membrane.

EGFR binding and activation results in many downstream processes. The EGFR tyrosine kinase domain activates Ras, which eventually leads to DNA synthesis and cell proliferation. The MAP kinase pathway is also activated through EGFR binding of Grb-2, with subsequent recruitment of the Ras GDP/GTP exchange factor Sos, for intracellular binding to the activated EGFR. EGFR tyrosine kinase activity also influences the progression of cells from G1 to S phase. While the specific functions of EGFR activity are still a subject of scientific research, the general function of EGFR is indicated to be cellular growth, proliferation, and differentiation. As a specific example, EGFR agonism with amphiregulin and other ligands has been shown to induce ductal and lobuloalveolar development, demonstrating its effects on proliferation of mammary glands and ductal development.

Mechanism

EGFR signaling commences with ligand binding. Ligand binding to the extracellular region of the receptor results in dimerization of the receptors. Homodimerization of EGFR receptors, in addition to heterodimerization of the EGFR with any of the other ErbB receptors, results in activation. It is important to note that homodimerization of the ErbB3 receptor does not result in this same active configuration, and ErbB3 receptors are only active after heterodimerization with an alternate ErbB receptor, such as EGFR.

After ligand binding and dimerization, autophosphorylation of specific intracellular tyrosine kinase residues induces formation that allows binding sites for signal transduction substrates. Substrates include phospholipase C-gamma 1 (PLC-gamma1), GTPase-activating protein (GAP) and the syp phosphotyrosine phosphatase. The tyrosine kinase domain can also bind adapter proteins such as the srs homology and collagen (Shc) protein and Grb-2. Altering all of the specific tyrosine kinase autophosphorylation sites results in significantly decreased substrate binding. However, altering only one of the sites can be compensated by binding to the others. Substrate binding leads to downstream signaling, facilitating cell growth and proliferation.

Inactivation of the EGFR is achieved by internalization of the receptor with subsequent lysosomal degradation. Internalization is dependent on tyrosine kinase activity, and activated receptors are internalized. Additional inactivation can be achieved by phosphorylation of serine and threonine residues in the cytoplasmic domain, with subsequent receptor desensitization and reduction of downstream signaling. 

Pathophysiology

EGFR has demonstrated expression on vascular endothelial cells, HeLa cells, conjunctiva cells, vascular and uterine smooth muscle cells, keratinocytes, amniotic cells, placental membranes, HeLa cells and normal skin fibroblasts. It is no surprise that many cancers have been associated with upregulation of EGFR and overexpression has been identified in the majority of solid tumors. Associated cancers include breast, head-and-neck, non-small-cell lung and squamous cell lung cancers, renal cell, ovarian, colon, bladder, pancreatic cancer, and gliomas. While normal cells express 40,000 to 100,000 EGFR receptors, cancer cells may express up to 2,000,000 receptors. Stimulation of overexpressed EGFR receptors may contribute to the pathology of cancer by inducing cancer-cell proliferation while simultaneously blocking apoptosis, by activating invasion and metastasis of hyperproliferative cells and by stimulating tumor-induced neovascularization. The degree of overexpression correlates with tumor progression, resistance to chemotherapy and a poor prognosis. In addition to their role in cancer cells, EGFR overexpression has been implicated in neurodegenerative diseases. In Alzheimer disease, mutations in presenilin 1 (PS1) contribute to the pathophysiology of the disease. PS1 is also involved in the transportation and production of EGFR. Neurites in proximity to the neuritic plaques found in Alzheimer disease show strong EGFR immunoreactivity and excess EGF is known to induce neuronal death. Although the precise mechanism of this relationship is unclear, recent research indicates that there is a role for EGFR overexpression in neurodegenerative disease as well.[10]

Clinical Significance

Given the involvement of EGFR in the pathology of cancers, EGFR inhibitors have been considered as potential therapeutic agents for cancer. Currently, 2 mechanisms of inhibition are used to inhibit EGFR:

  • Anti-EGFR monoclonal antibodies
    • Anti-EGFR monoclonal antibodies (cetuximab, panitumumab, erlotinib, and gefitinib) act as competitive inhibitors of EGFR ligand binding
  • EGFR tyrosine kinase inhibitors
    • EGFR tyrosine kinase inhibitors (gefitinib, erlotinib, brigatinib, lapatinib) are small molecules that bind and inhibit the EGFR intracellular tyrosine kinase, which prevents further downstream activation

These therapies have been approved for treatment of some cancers, including lung cancer and colon cancer.   A side effect of both classes of medications is a papulopustular eruption, seen in 90% of patients. 

Although these treatments are promising, resistance is often seen. The T790M Mutation and MET oncogene are the 2 primary sources of resistance.


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Biochemistry, Epidermal Growth Factor Receptor - Questions

Take a quiz of the questions on this article.

Take Quiz
The epidermal growth factor receptor has two binding sites for targeted molecules to act. They include which of the following?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which member of the ErbB tyrosine kinase family is not activated by homodimerization?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What type of receptor is Her2/neu?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What pathology is associated with overexpression of epidermal growth factor?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is the most common side effect of anti-endothelial growth factor receptor (EGFR) agents?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
How are activated epidermal growth factor receptors inactivated?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Biochemistry, Epidermal Growth Factor Receptor - References

References

Seebacher NA,Stacy AE,Porter GM,Merlot AM, Clinical development of targeted and immune based anti-cancer therapies. Journal of experimental     [PubMed]
Mizukami T,Izawa N,Nakajima TE,Sunakawa Y, Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives. Drugs. 2019 Apr 9;     [PubMed]
Martin-Fernandez ML,Clarke DT,Roberts SK,Zanetti-Domingues LC,Gervasio FL, Structure and Dynamics of the EGF Receptor as Revealed by Experiments and Simulations and Its Relevance to Non-Small Cell Lung Cancer. Cells. 2019 Apr 5;     [PubMed]
D'Oronzo S,Coleman R,Brown J,Silvestris F, Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management. Journal of bone oncology. 2019 Apr;     [PubMed]
Liu X,Liu S,Lyu H,Riker AI,Zhang Y,Liu B, Development of Effective Therapeutics Targeting HER3 for Cancer Treatment. Biological procedures online. 2019;     [PubMed]
Chia PL,Scott AM,John T, Epidermal growth factor receptor (EGFR)-targeted therapies in Mesothelioma. Expert opinion on drug delivery. 2019 Mar 27;     [PubMed]
Venur VA,Cohen JV,Brastianos PK, Targeting Molecular Pathways in Intracranial Metastatic Disease. Frontiers in oncology. 2019;     [PubMed]
Wang S,Zhang Z,Peng H,Zeng K, Recent advances on the roles of epidermal growth factor receptor in psoriasis. American journal of translational research. 2019;     [PubMed]
Muller KE,Marotti JD,Tafe LJ, Pathologic Features and Clinical Implications of Breast Cancer With HER2 Intratumoral Genetic Heterogeneity. American journal of clinical pathology. 2019 Mar 20;     [PubMed]
Le T,Gerber DE, Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used? Cancers. 2019 Mar 15;     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Neurology. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Neurology, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Neurology, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Neurology. When it is time for the Neurology board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Neurology.